Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDXHCI002 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0840 -0.00493
PDXHCI002 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0632 -0.00350
PDXHCI002 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0437 -0.00126
PDXHCI002 Cediranib
0.031623
VEGFR/cKIT
RTK
 0.9564 0.00419
PDXHCI002 Cediranib
0.1
VEGFR/cKIT
RTK
 0.9039 0.00132
PDXHCI002 Cediranib
0.31623
VEGFR/cKIT
RTK
 0.7860 0.01648
PDXHCI002 Cediranib
1.0
VEGFR/cKIT
RTK
 0.6308 0.01865
PDXHCI002 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.2469 0.04779
PDXHCI002 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.4324 0.52102
PDXHCI002 Cabozantinib
0.001
VEGFR2/MET
RTK
 1.0344 0.00007
PDXHCI002 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0320 0.00253
PDXHCI002 Cabozantinib
0.01
VEGFR2/MET
RTK
 1.1138 0.00376
PDXHCI002 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0508 0.00411
PDXHCI002 Cabozantinib
0.1
VEGFR2/MET
RTK
 1.0421 0.00348
PDXHCI002 Cabozantinib
0.31623
VEGFR2/MET
RTK
 0.9990 0.00271
PDXHCI002 Cabozantinib
1.0
VEGFR2/MET
RTK
 0.9644 0.01779
PDXHCI002 Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.8742 0.02262
PDXHCI002 Cabozantinib
10.0
VEGFR2/MET
RTK
 0.2341 0.16574
SUM149PT Abemaciclib
0.001
CDK4/6
Cell cycle
 0.9844 -0.00204
SUM149PT Abemaciclib
0.0031623
CDK4/6
Cell cycle
 1.0233 -0.00672
SUM149PT Abemaciclib
0.01
CDK4/6
Cell cycle
 0.8811 -0.00156
SUM149PT Abemaciclib
0.031623
CDK4/6
Cell cycle
 0.7731 -0.00535
SUM149PT Abemaciclib
0.1
CDK4/6
Cell cycle
 0.6688 -0.00395
SUM149PT Abemaciclib
0.31623
CDK4/6
Cell cycle
 0.5546 -0.00436
SUM149PT Abemaciclib
1.0
CDK4/6
Cell cycle
 0.4454 0.00214